Study to investigate safety and tolerability single ascending doses of AZD4017
Study identifier:D2060C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Single-blind, Placebo-controlled, Single-centre, Phase 1Study in Healthy Volunteers to Assess the Safety, Tolerability andPharmacokinetics of AZD4017 after Single Ascending Oral Doses
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD4017, Placebo
Sex
Male
Actual Enrollment
40
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Nov 2008
Primary Completion Date: -
Study Completion Date: 01 Mar 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD4017 in ascending doses (start dose 2mg) | Drug: AZD4017 ascending single doses (start dose 2 mg), oral suspension |
| Placebo Comparator: 2 Placebo | Drug: Placebo Placebo |
Contacts
Investigators
Principal Investigator
Marianne Hartford
Sahlgrenska University Sweden
